Vitiligo in the United States: A ten-year study of patient characteristics, comorbidities, and treatment patterns

Authors

  • Margaret Y. Huang Keck School of Medicine of University of Southern California, Los Angeles, California Author
  • Kimberly Smart Keck School of Medicine of University of Southern California, Los Angeles, California Author
  • Kathryn Lee Saint Louis University School of Medicine, Saint Louis, Missouri Author
  • Paige Kingston Keck School of Medicine of University of Southern California, Los Angeles, California Author
  • Danielle Yee Keck School of Medicine of University of Southern California, Los Angeles, California Author
  • Hannah Peterson Loma Linda University School of Medicine, Loma Linda, California Author
  • Edwin Korouri Rosalind Franklin University of Medicine and Science, Chicago Medical School, North Chicago, Illinois Author
  • April W. Armstrong Division of Dermatology, University of California, Los Angeles, Los Angeles, California Author

DOI:

https://doi.org/10.25251/39x13b67

Keywords:

autoimmune disorders, epidemiology, National Ambulatory Medical Care Survey, patient characteristics, population study, vitiligo

References

1. Bergqvist C, Ezzedine K. Vitiligo: A Review. Dermatology. 2020;236(6):571-592. Epub 2020 Mar 10. [PMID: 32155629].

2. Gandhi K, Ezzedine K, Anastassopoulos KP, et al. Prevalence of Vitiligo Among Adults in the United States. JAMA Dermatol. 2022 Jan 1;158(1):43-50. [PMID: 34787670].

3. Alikhan A, Felsten LM, Daly M, et al. Vitiligo: a comprehensive overview Part I. Introduction, epidemiology, quality of life, diagnosis, differential diagnosis, associations, histopathology, etiology, and work-up. J Am Acad Dermatol. 2011 Sep;65(3):473-491. [PMID: 21839315].

4. Kyriakis KP, Palamaras I, Tsele E, et al. Case detection rates of vitiligo by gender and age. Int J Dermatol. 2009 Mar;48(3):328-9. [PMID: 19261030].

5. Sparber F, De Gregorio C, Steckholzer S, et al. The Skin Commensal Yeast Malassezia Triggers a Type 17 Response that Coordinates Anti-fungal Immunity and Exacerbates Skin Inflammation. Cell Host Microbe. 2019;25(3):389-403.e6. [PMID: 30870621].

6. Singh RK, Lee KM, Vujkovic-Cvijin I, et al. The role of IL-17 in vitiligo: A review. Autoimmun Rev. 2016;15(4):397-404. [PMID: 26804758].

7. Schwartz RA, Janusz CA, Janniger CK. Seborrheic dermatitis: an overview. Am Fam Physician. 2006 Jul 1;74(1):125-30. [PMID: 16848386].

8. Oripelaye MM, Olanrewaju FO, Onayemi OE, et al. Seborrheic Dermatitis Induced Koebnerization: A Probable Outcome Determinant in Vitiligo. Intern Med. 2017;7:3.

9. Ben Ahmed M, Zaraa I, Rekik R, et al. Functional defects of peripheral regulatory T lymphocytes in patients with progressive vitiligo. Pigment Cell Melanoma Res. 2012;25(1):99-109. [PMID: 21985183].

10. Lacovelli P, Sinagra JL, Vidolin AP, et al. Relevance of thyroiditis and of other autoimmune diseases in children with vitiligo. Dermatology. 2005;210(1):26-30. [PMID: 15604541].

11. Vrijman C, Kroon MW, Limpens J, et al. The prevalence of thyroid disease in patients with vitiligo: a systematic review. Br J Dermatol. 2012;167(6):1224-1235. [PMID: 22860695].

12. Czajkowski R, Męcińska-Jundziłł K. Current aspects of vitiligo genetics. Postepy Dermatol Alergol. 2014;31(4):247-255. [PMID: 25254010].

13. Gill L, Zarbo A, Isedeh P, et al. Comorbid autoimmune diseases in patients with vitiligo: A cross-sectional study. J Am Acad Dermatol. 2016 Feb;74(2):295-302. [PMID: 26518171].

14. Chen YT, Chen YJ, Hwang CY, et al. Comorbidity profiles in association with vitiligo: a nationwide population-based study in Taiwan. J Eur Acad Dermatol Venereol. 2015 Jul;29(7):1362-9. [PMID: 25510261].

15. Singh RK, Lee KM, Vujkovic-Cvijin I, et al. The role of IL-17 in vitiligo: A review. Autoimmun Rev. 2016;15(4):397-404. [PMID: 26804758].

16. Verma D, Hussain K, Namiq KS, et al. Vitiligo: The Association With Metabolic Syndrome and the Role of Simvastatin as an Immunomodulator. Cureus. 2021 Mar 22;13(3):e14029. [PMID: 33898117].

17. Mitra S, De Sarkar S, Pradhan A, et al. Levels of oxidative damage and proinflammatory cytokines are enhanced in patients with active vitiligo. Free Radic Res. 2017;51(11-12):986-994. [PMID: 29182456].

18. Ataş H, Gönül M. Increased Risk of Metabolic Syndrome in Patients with Vitiligo. Balkan Med J. 2017 May 5;34(3):219-225. [PMID: 28443562].

19. Grossmann MC, Haidari W, Feldman SR. A Review on the Use of Topical Ruxolitinib for the Treatment of Vitiligo. J Drugs Dermatol. 2023 Jul 1;22(7):664-667. [PMID: 37410047].

20. Rosmarin D, Passeron T, Pandya AG, Grimes P, Harris JE, Desai SR, Lebwohl M, Ruer-Mulard M, Seneschal J, Wolkerstorfer A, Kornacki D, Sun K, Butler K, Ezzedine K; TRuE-V Study Group. Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for Vitiligo. N Engl J Med. 2022 Oct 20;387(16):1445-1455. [PMID: 36260792].

Downloads

Published

05/09/2026

Issue

Vol. 32 No. 2 (2026): Dermatology Online Journal

Section

Letter

License

Copyright (c) 2026 Margaret Y. Huang, Kimberly Smart, Kathryn Lee, Paige Kingston, Danielle Yee, Hannah Peterson, Edwin Korouri, April W. Armstrong (Author)

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.